Jounce Therapeutics
Latest round
- Series B
Last raised
- Apr 2015
Total raised
- $88M
Investors
- 9
About Jounce Therapeutics
Based in the US, Jounce Therapeutics, Inc.Jounce Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, US.84 mn.25 mn in a Private Placement/Follow on. The company has executed a total of 5 deals, with the most recent deal occurring on March 9, 2021.Jounce Therapeutics, Inc. specializes in the development of immune-oncology therapies specifically targeting cancer treatment. The company aims to expand its offerings in the immune-oncology sector, targeting new markets in North America and Europe. Future product launches and advancements in therapeutic solutions are anticipated as part of their growth strategy.
Who invested in Jounce Therapeutics
9 investors across 2 rounds
See all investors in Jounce Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Jounce Therapeutics
Who invested in Jounce Therapeutics?
Jounce Therapeutics has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Jounce Therapeutics raised?
Jounce Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Jounce Therapeutics last raise money?
Jounce Therapeutics's most recent round on record is a Series B, in Apr 2015.
What does Jounce Therapeutics do?
Based in the US, Jounce Therapeutics, Inc.
Where is Jounce Therapeutics headquartered?
Jounce Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like Jounce Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Jounce Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Jounce Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.